Collegium Pharmaceutical (COLL) Financials

$27.12 +0.39 (+1.46%)

Closing price 04:00 PM Eastern

Extended Trading

$27.14 +0.02 (+0.07%)

As of 04:20 PM Eastern

Annual Income Statements for Collegium Pharmaceutical

This table shows Collegium Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	0.00	-27	-94	-75	-39	-23	27	72	-25	48	69
Consolidated Net Income / (Loss)	0.00	-27	-94	-75	-39	-23	27	72	-25	48	69
Net Income / (Loss) Continuing Operations	0.00	-27	-94	-75	-39	-23	27	72	-25	48	69
Total Pre-Tax Income	0.00	-27	-94	-75	-39	-23	28	-3.37	-29	76	99
Total Operating Income	0.00	-27	-94	-75	-21	-24	56	18	33	167	170
Total Gross Profit	0.00	0.00	1.50	26	115	103	180	151	209	326	377
Total Revenue	0.00	0.00	1.71	28	280	297	310	277	464	567	631
Operating Revenue	-	0.00	1.71	28	280	297	310	277	464	567	631
Total Cost of Revenue	0.00	0.00	0.21	2.60	166	194	130	126	254	241	254
Operating Cost of Revenue	-	0.00	0.21	2.60	166	194	130	126	254	241	254
Total Operating Expenses	0.00	27	96	101	135	127	124	133	176	159	207
Selling, General & Admin Expense	-	19	81	93	127	116	114	119	172	159	210
Research & Development Expense	-	7.98	15	8.57	8.66	10	9.77	9.45	3.98	0.00	0.00
Other Special Charges / (Income)	-	-	-	-	-	0.00	0.00	-	0.00	0.00	-2.91
Total Other Income / (Expense), net	0.00	-0.35	-0.09	0.58	-18	1.03	-29	-21	-62	-91	-71
Interest Expense	-	-0.09	0.09	-	20	0.91	29	21	63	107	85
Interest & Investment Income	-	-0.44	-	0.58	1.69	1.94	0.23	0.01	1.05	16	14
Income Tax Expense	-	-	-	-	0.00	0.00	0.83	-75	-3.85	28	29
Basic Earnings per Share	($22.72)	($1.48)	($3.88)	($2.47)	($1.19)	($0.68)	$0.78	$2.05	($0.74)	$1.43	$2.14
Weighted Average Basic Shares Outstanding	934.00K	13.54M	24.26M	30.27M	32.95M	33.45M	34.41M	34.94M	33.83M	33.74M	32.27M
Diluted Earnings per Share	($22.72)	($1.48)	($3.88)	($2.47)	($1.19)	($0.68)	$0.76	$1.86	($0.74)	$1.29	$1.86
Weighted Average Diluted Shares Outstanding	934.00K	13.54M	24.26M	30.27M	32.95M	33.45M	35.15M	41.05M	33.83M	41.79M	40.42M
Weighted Average Basic & Diluted Shares Outstanding	934.00K	13.54M	24.26M	30.27M	32.95M	33.45M	34.76M	33.38M	34.07M	31.96M	31.49M

This table shows Collegium Pharmaceutical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	0.46	-7.20	-17	13	21	32	28	20	9.34	13
Consolidated Net Income / (Loss)	0.46	-7.20	-17	13	21	32	28	20	9.34	13
Net Income / (Loss) Continuing Operations	0.46	-7.20	-17	13	21	32	28	20	9.34	13
Total Pre-Tax Income	1.43	-7.79	-18	18	29	47	37	29	16	17
Total Operating Income	20	12	25	36	45	62	49	47	35	38
Total Gross Profit	59	50	77	74	80	95	91	91	97	98
Total Revenue	127	130	145	136	137	150	145	145	159	182
Operating Revenue	127	130	145	136	137	150	145	145	159	182
Total Cost of Revenue	68	80	67	62	56	55	53	54	63	84
Operating Cost of Revenue	68	80	67	62	56	55	53	54	63	84
Total Operating Expenses	38	38	53	38	35	33	42	43	62	60
Selling, General & Admin Expense	38	38	53	38	35	33	42	43	62	63
Total Other Income / (Expense), net	-19	-20	-42	-18	-16	-15	-13	-18	-19	-21
Interest Expense	19	21	45	22	21	19	17	23	23	23
Interest & Investment Income	0.01	1.03	2.75	4.03	4.54	4.30	4.49	4.40	3.28	1.81
Income Tax Expense	0.98	-0.59	-0.13	4.79	8.15	15	8.91	9.49	6.25	4.73
Basic Earnings per Share	$0.01	($0.21)	($0.51)	$0.38	$0.61	$0.95	$0.86	$0.60	$0.29	$0.39
Weighted Average Basic Shares Outstanding	34.06M	33.83M	34.32M	34.62M	33.74M	33.74M	32.33M	32.43M	32.26M	32.27M
Diluted Earnings per Share	$0.01	($0.21)	($0.51)	$0.34	$0.53	$0.93	$0.71	$0.52	$0.27	$0.36
Weighted Average Diluted Shares Outstanding	34.57M	33.83M	34.32M	42.85M	42.06M	41.79M	41.44M	40.38M	40.16M	40.42M
Weighted Average Basic & Diluted Shares Outstanding	33.57M	34.07M	34.59M	34.73M	32.61M	31.96M	32.72M	32.21M	32.25M	31.49M

This table details how cash moves in and out of Collegium Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-5.92	94	58	-35	28	23	6.64	12	-13	64	-143
Net Cash From Operating Activities	-18	-22	-75	-67	169	28	94	104	124	275	205
Net Cash From Continuing Operating Activities	-18	-22	-75	-67	169	28	94	104	124	275	205
Net Income / (Loss) Continuing Operations	-18	-27	-94	-75	-39	-23	27	72	-25	48	69
Consolidated Net Income / (Loss)	-18	-27	-94	-75	-39	-23	27	72	-25	48	69
Depreciation Expense	0.19	0.17	0.66	0.59	1.07	0.73	0.87	1.74	2.68	3.50	3.86
Amortization Expense	-0.03	-0.03	-0.03	-0.03	110	15	70	71	145	153	169
Non-Cash Adjustments To Reconcile Net Income	0.02	2.22	5.79	26	140	30	21	65	0.35	47	48
Changes in Operating Assets and Liabilities, net	-0.22	3.34	13	-18	-42	5.42	-24	-105	1.66	23	-85
Net Cash From Investing Activities	-0.01	-0.36	-2.98	-0.99	-24	-6.44	-374	-1.94	-574	-71	-288
Net Cash From Continuing Investing Activities	-0.01	-0.36	-2.98	-0.99	-24	-6.44	-374	-1.94	-574	-71	-288
Purchase of Property, Plant & Equipment	-0.01	-0.36	-0.48	-0.99	-5.48	-6.44	-5.55	-1.94	-1.62	-0.46	-1.65
Acquisitions	0.00	0.00	-2.50	-	-19	0.00	-368	0.00	-572	0.00	-268
Purchase of Investments	-	-	-	-	-	-	-	0.00	0.00	-92	-111
Sale and/or Maturity of Investments	-	-	-	-	-	-	-	0.00	0.00	22	93
Net Cash From Financing Activities	12	116	136	33	-117	2.04	286	-89	437	-140	-61
Net Cash From Continuing Financing Activities	12	116	136	33	-117	2.04	286	-89	437	-140	-61
Repayment of Debt	-0.03	-1.36	-2.67	-2.67	0.00	0.00	-49	-50	-75	-301	-272
Repurchase of Common Equity	-	-	-	-	-0.03	0.00	0.00	-48	-14	-75	-60
Issuance of Debt	12	0.00	-	-	10	0.00	330	0.00	518	235	0.00
Issuance of Common Equity	0.00	72	138	35	1.12	0.82	0.76	0.76	0.34	0.46	0.83
Other Financing Activities, net	0.01	0.52	0.44	0.67	-128	1.22	4.32	7.80	7.77	0.28	271
Cash Interest Paid	0.18	0.35	0.28	0.14	-	0.71	19	18	53	73	62
Cash Income Taxes Paid	-	-	-	-	0.00	0.00	0.48	3.01	10	24	52

This table details how cash moves in and out of Collegium Pharmaceutical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	11	40	96	13	-25	-20	-10	-56	-109	32
Net Cash From Operating Activities	43	66	28	100	74	73	62	67	-9.00	85
Net Cash From Continuing Operating Activities	43	66	28	100	74	73	62	67	-9.47	85
Net Income / (Loss) Continuing Operations	0.46	-7.20	-17	13	21	32	28	20	9.34	13
Consolidated Net Income / (Loss)	0.46	-7.20	-17	13	21	32	28	20	9.34	13
Depreciation Expense	0.49	0.83	0.82	0.90	0.84	0.95	0.92	0.95	0.95	1.04
Amortization Expense	40	45	40	40	38	36	36	35	41	57
Non-Cash Adjustments To Reconcile Net Income	-0.21	-5.16	-0.16	19	39	-11	-2.00	36	10	4.23
Changes in Operating Assets and Liabilities, net	2.02	33	4.68	27	-24	15	-0.58	-24	-71	11
Net Cash From Investing Activities	-0.11	-0.94	-0.18	-42	-3.82	-25	-18	-8.91	-249	-12
Net Cash From Continuing Investing Activities	-0.11	-0.94	-0.18	-42	-3.82	-25	-18	-8.91	-249	-12
Purchase of Property, Plant & Equipment	-0.11	-0.94	-0.18	-0.06	-0.07	-0.16	-0.57	-0.27	-0.24	-0.57
Purchase of Investments	-	-	0.00	-42	-9.76	-41	-39	-34	-11	-27
Sale and/or Maturity of Investments	-	-	0.00	-	6.00	16	22	26	29	16
Net Cash From Financing Activities	-31	-26	68	-45	-95	-68	-54	-114	149	-41
Net Cash From Continuing Financing Activities	-31	-26	68	-45	-95	-68	-54	-114	149	-41
Repayment of Debt	-25	-25	-164	-46	-46	-46	-46	-79	-165	17
Repurchase of Common Equity	-6.42	-7.64	0.00	-	-50	-25	0.00	-35	-	-25
Issuance of Debt	-	-	236	-0.43	-	-	0.00	-	313	-313
Other Financing Activities, net	0.04	6.82	-3.89	1.03	0.13	3.01	-8.67	-0.16	0.01	280
Cash Interest Paid	18	17	19	18	20	16	17	12	18	15
Cash Income Taxes Paid	3.26	0.36	0.74	9.27	7.28	6.91	0.17	36	16	0.62

This table presents Collegium Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	5.09	98	162	136	291	306	644	692	1,174	1,143	1,664
Total Current Assets	4.50	97	159	133	238	256	278	316	420	538	482
Cash & Equivalents	1.63	96	153	119	147	170	174	186	174	239	71
Restricted Cash	-	-	-	-	-	-	-	-	-	0.00	25
Short-Term Investments	-	-	-	-	-	-	-	-	0.00	72	92
Accounts Receivable	-	0.00	2.13	9.97	78	73	83	106	183	180	229
Inventories, net	-	0.00	1.32	1.81	7.82	9.64	16	17	47	32	36
Prepaid Expenses	0.53	1.19	1.91	3.01	5.12	3.11	4.84	5.88	17	15	30
Plant, Property, & Equipment, net	0.51	0.74	1.04	1.83	9.27	12	19	19	20	16	14
Total Noncurrent Assets	0.08	0.10	2.40	0.26	44	39	347	357	735	590	1,167
Goodwill	-	0.00	2.10	-	44	30	336	0.00	134	134	162
Intangible Assets	-	-	-	-	-	-	-	269	567	422	891
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	-	-	78	24	26	98
Other Noncurrent Operating Assets	-	0.00	0.20	0.16	0.20	9.23	8.51	7.73	6.96	7.90	15
Total Liabilities & Shareholders' Equity	5.09	98	162	136	291	306	644	692	1,174	1,143	1,664
Total Liabilities	17	13	27	31	200	219	458	489	979	948	1,435
Total Current Liabilities	10	8.43	26	31	189	202	239	280	434	458	510
Short-Term Debt	6.19	2.67	-	1.48	1.64	3.83	47	48	163	183	94
Accounts Payable	2.21	3.54	9.11	5.68	12	6.25	10	4.19	3.49	8.69	3.93
Accrued Expenses	1.96	2.23	8.88	24	175	191	181	226	267	265	411
Other Current Liabilities	0.06	-	-	-	-	0.66	0.73	0.81	1.11	0.99	1.27
Total Noncurrent Liabilities	6.91	4.21	1.51	0.00	11	17	218	210	546	490	925
Long-Term Debt	6.81	4.15	1.48	-	9.86	7.67	210	202	538	484	788
Noncurrent Deferred Revenue	-	-	-	-	-	-	-	-	-	0.00	10
Other Noncurrent Operating Liabilities	0.10	0.07	0.03	-	0.68	9.44	8.77	7.95	7.11	6.12	127
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-89	85	135	104	92	87	186	203	195	195	229
Total Preferred & Common Equity	-89	85	135	104	92	87	186	203	195	195	229
Preferred Stock	-	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00
Total Common Equity	-89	85	135	104	92	87	186	203	195	195	229
Common Stock	12	214	358	402	429	447	519	502	538	566	590
Retained Earnings	-102	-129	-223	-298	-337	-360	-333	-256	-281	-233	-164
Treasury Stock	-0.00	-0.00	-	-	-	-	-	-43	-62	-137	-198
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	-	-	-	-	0.00	0.01	0.06

This table presents Collegium Pharmaceutical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	1,201	1,214	1,214	1,178	1,114	1,053	1,635
Total Current Assets	405	498	537	537	539	510	444
Cash & Equivalents	134	269	284	259	229	173	39
Restricted Cash	-	-	-	-	-	-	25
Short-Term Investments	-	-	42	46	89	99	81
Accounts Receivable	195	179	167	182	175	184	228
Inventories, net	65	33	26	34	31	28	38
Prepaid Expenses	11	17	18	17	15	27	32
Plant, Property, & Equipment, net	20	19	18	17	15	15	15
Total Noncurrent Assets	776	697	659	624	560	528	1,177
Goodwill	130	134	134	134	134	134	146
Intangible Assets	610	530	493	456	387	353	947
Noncurrent Deferred & Refundable Income Taxes	26	24	25	26	31	34	73
Other Noncurrent Operating Assets	7.12	6.75	6.53	6.98	6.77	6.45	11
Total Liabilities & Shareholders' Equity	1,201	1,214	1,214	1,178	1,114	1,053	1,635
Total Liabilities	1,004	1,035	1,013	999	892	837	1,401
Total Current Liabilities	414	413	435	465	446	462	459
Short-Term Debt	142	183	183	183	183	183	94
Accounts Payable	7.64	2.99	2.42	3.65	6.02	2.41	3.14
Accrued Expenses	264	225	248	277	256	275	361
Other Current Liabilities	1.18	1.04	0.97	0.96	1.01	1.04	1.27
Total Noncurrent Liabilities	589	622	578	534	446	375	941
Long-Term Debt	582	615	571	528	440	369	803
Noncurrent Deferred Revenue	-	-	-	-	-	-	10
Other Noncurrent Operating Liabilities	7.35	6.87	6.63	6.38	5.86	5.59	129
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	197	180	201	179	222	217	234
Total Preferred & Common Equity	197	180	201	179	222	217	234
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	197	180	201	179	222	217	234
Common Stock	526	540	549	546	565	568	583
Retained Earnings	-274	-299	-286	-265	-205	-186	-177
Treasury Stock	-54	-62	-62	-102	-137	-165	-172
Accumulated Other Comprehensive Income / (Loss)	-	-	-0.04	-0.05	-0.12	-0.18	0.39

This table displays calculated financial ratios and metrics derived from Collegium Pharmaceutical's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	1,564.29%	884.73%	5.81%	4.49%	-10.69%	67.56%	22.17%	11.41%
EBITDA Growth	101.01%	-16,831.25%	-249.13%	19.87%	220.48%	-109.16%	1,633.62%	-29.04%	100.71%	79.25%	6.00%
EBIT Growth	100.00%	0.00%	-249.66%	19.81%	72.58%	-14.81%	336.79%	-68.65%	89.01%	401.10%	1.76%
NOPAT Growth	100.00%	0.00%	-249.66%	19.81%	72.58%	-14.81%	428.09%	-77.38%	89.01%	355.18%	12.34%
Net Income Growth	100.00%	0.00%	-245.54%	20.51%	47.74%	41.93%	217.74%	167.33%	-134.96%	292.60%	43.68%
EPS Growth	-459.61%	93.49%	-162.16%	36.34%	51.82%	42.86%	211.76%	144.74%	-139.78%	274.32%	44.19%
Operating Cash Flow Growth	-8.57%	-20.17%	-248.00%	10.71%	352.75%	-83.60%	238.13%	10.24%	19.96%	121.16%	-25.39%
Free Cash Flow Firm Growth	0.00%	-1,774.46%	-232.82%	-6.97%	128.02%	-31.06%	-2,692.71%	105.25%	-3,009.78%	163.31%	-191.79%
Invested Capital Growth	0.00%	-312.34%	-333.23%	21.85%	-229.04%	-63.24%	474.83%	-0.94%	172.62%	-23.28%	67.11%
Revenue Q/Q Growth	0.00%	0.00%	319.36%	49.99%	28.76%	0.26%	0.67%	-15.01%	28.27%	3.68%	5.37%
EBITDA Q/Q Growth	0.00%	-346.59%	-89.35%	39.88%	97.42%	-148.44%	35.35%	-36.07%	68.46%	14.63%	-0.83%
EBIT Q/Q Growth	0.00%	-351.30%	-89.23%	39.88%	58.02%	-128.92%	44.69%	-73.59%	365.28%	42.67%	-12.19%
NOPAT Q/Q Growth	0.00%	-275.91%	-89.23%	39.88%	58.02%	-128.92%	40.34%	-92.36%	365.28%	113.62%	-10.94%
Net Income Q/Q Growth	0.00%	-2,060.79%	-16.53%	11.95%	40.37%	-98.71%	52.06%	-30.91%	41.63%	434.11%	-21.90%
EPS Q/Q Growth	0.00%	78.83%	-108.60%	17.11%	39.90%	-106.06%	55.10%	-29.01%	32.11%	760.00%	-23.46%
Operating Cash Flow Q/Q Growth	0.00%	-6.79%	-23.64%	12.97%	48.84%	-48.94%	7.95%	15.15%	32.01%	2.62%	5.84%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-93.29%	37.59%	115.43%	-90.04%	2.74%	-91.72%	19.78%	9.69%	6.01%
Invested Capital Q/Q Growth	0.00%	13.44%	-41.28%	-42.42%	-174.03%	-22.40%	-1.95%	3.92%	-8.23%	-5.52%	-6.39%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	87.55%	90.89%	40.92%	34.73%	58.01%	54.40%	45.15%	57.55%	59.76%
EBITDA Margin	0.00%	0.00%	-5,462.36%	-262.98%	32.18%	-2.79%	40.89%	32.49%	38.92%	57.10%	54.33%
Operating Margin	0.00%	0.00%	-5,498.66%	-264.95%	-7.38%	-8.00%	18.14%	6.37%	7.18%	29.46%	26.91%
EBIT Margin	0.00%	0.00%	-5,498.66%	-264.95%	-7.38%	-8.00%	18.14%	6.37%	7.18%	29.46%	26.91%
Profit (Net Income) Margin	0.00%	0.00%	-5,504.15%	-262.91%	-13.95%	-7.66%	8.63%	25.83%	-5.39%	8.50%	10.96%
Tax Burden Percent	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	96.99%	-2,119.65%	86.67%	63.59%	70.20%
Interest Burden Percent	0.00%	101.29%	100.10%	99.23%	189.16%	95.68%	49.05%	-19.14%	-86.58%	45.36%	58.02%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.01%	0.00%	0.00%	36.41%	29.80%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	55.83%	4.65%	4.74%	16.70%	16.18%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	127.00%	88.33%	-11.76%	3.53%	6.64%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-36.27%	32.12%	-17.31%	7.98%	16.44%
Return on Equity (ROE)	0.00%	-74.84%	-85.62%	-62.65%	-39.99%	-25.39%	19.57%	36.77%	-12.57%	24.68%	32.62%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-106.21%	5.60%	-87.91%	43.04%	-34.07%
Operating Return on Assets (OROA)	0.00%	0.00%	-72.44%	-50.71%	-9.69%	-7.95%	11.84%	2.64%	3.57%	14.41%	12.11%
Return on Assets (ROA)	0.00%	0.00%	-72.52%	-50.32%	-18.34%	-7.61%	5.63%	10.71%	-2.68%	4.16%	4.93%
Return on Common Equity (ROCE)	0.00%	4.39%	-85.62%	-62.65%	-39.99%	-25.39%	19.57%	36.77%	-12.57%	24.68%	32.62%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-32.04%	-69.81%	-71.93%	-42.72%	-25.99%	14.38%	35.24%	-12.83%	24.64%	30.23%
Net Operating Profit after Tax (NOPAT)	0.00	-19	-66	-53	-14	-17	55	12	23	106	119
NOPAT Margin	0.00%	0.00%	-3,849.06%	-185.46%	-5.16%	-5.60%	17.59%	4.46%	5.03%	18.73%	18.89%
Net Nonoperating Expense Percent (NNEP)	0.00%	-21.68%	-23.52%	-16.39%	-19.53%	-4.15%	-71.17%	-83.68%	16.50%	13.16%	9.53%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	2.60%	12.31%	10.74%
Cost of Revenue to Revenue	0.00%	0.00%	12.45%	9.11%	59.08%	65.27%	41.99%	45.60%	54.85%	42.45%	40.24%
SG&A Expenses to Revenue	0.00%	0.00%	4,712.57%	325.73%	45.20%	39.25%	36.72%	42.97%	37.11%	28.09%	33.31%
R&D to Revenue	0.00%	0.00%	873.64%	30.10%	3.09%	3.49%	3.15%	3.41%	0.86%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	5,586.21%	355.84%	48.29%	42.73%	39.87%	48.03%	37.97%	28.09%	32.85%
Earnings before Interest and Taxes (EBIT)	0.00	-27	-94	-75	-21	-24	56	18	33	167	170
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.16	-27	-93	-75	90	-8.27	127	90	181	324	343
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	6.69	3.30	5.78	6.23	7.89	3.72	3.18	4.00	5.14	4.04
Price to Tangible Book Value (P/TBV)	0.00	6.69	3.35	5.78	12.06	11.91	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	260.35	21.11	2.04	2.33	2.23	2.33	1.68	1.77	1.46
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	25.89	9.03	0.00	20.84	13.35
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.86%	11.08%	0.00%	4.80%	7.49%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	2.91	2.69	1.82	2.46	1.75
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	171.67	16.99	1.55	1.79	2.50	2.56	2.82	2.40	2.56
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	4.83	0.00	6.12	7.89	7.23	4.20	4.72
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	13.79	40.24	39.20	8.15	9.52
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	14.22	57.48	56.00	12.81	13.56
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	2.57	19.13	8.26	6.85	10.51	4.95	7.89
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	27.52	48.69	0.00	47.74	0.00	4.97	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-1.06	0.08	0.01	0.01	0.13	0.13	1.38	1.23	3.60	3.41	3.85
Long-Term Debt to Equity	-0.56	0.05	0.01	0.00	0.11	0.09	1.13	0.99	2.76	2.48	3.44
Financial Leverage	-0.92	-1.07	-1.09	-1.13	-1.29	-1.64	-0.29	0.36	1.47	2.26	2.48
Leverage Ratio	-0.42	1.41	1.18	1.25	2.18	3.34	3.47	3.43	4.69	5.94	6.62
Compound Leverage Factor	0.00	1.43	1.18	1.24	4.13	3.19	1.70	-0.66	-4.06	2.69	3.84
Debt to Total Capital	1,698.04%	7.41%	1.08%	1.40%	11.16%	11.62%	58.02%	55.19%	78.25%	77.34%	79.39%
Short-Term Debt to Total Capital	808.62%	2.90%	0.00%	1.40%	1.59%	3.87%	10.72%	10.68%	18.14%	21.25%	8.42%
Long-Term Debt to Total Capital	889.43%	4.51%	1.08%	0.00%	9.56%	7.75%	47.30%	44.52%	60.11%	56.09%	70.96%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	10,066.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-11,664.23%	92.59%	98.92%	98.60%	88.84%	88.38%	41.98%	44.81%	21.75%	22.66%	20.61%
Debt to EBITDA	81.29	-0.25	-0.02	-0.02	0.13	-1.39	2.03	2.78	3.88	2.06	2.57
Net Debt to EBITDA	71.08	3.32	1.62	1.57	-1.50	19.18	0.65	0.71	2.92	1.10	2.02
Long-Term Debt to EBITDA	42.58	-0.15	-0.02	0.00	0.11	-0.93	1.65	2.24	2.98	1.50	2.30
Debt to NOPAT	0.00	-0.36	-0.02	-0.03	-0.79	-0.69	4.71	20.26	30.05	6.28	7.39
Net Debt to NOPAT	0.00	4.72	2.30	2.22	9.33	9.54	1.52	5.15	22.61	3.36	5.82
Long-Term Debt to NOPAT	0.00	-0.22	-0.02	0.00	-0.68	-0.46	3.84	16.34	23.09	4.56	6.61
Altman Z-Score	0.00	25.32	7.01	7.65	1.02	1.17	1.02	0.82	0.62	1.41	0.95
Noncontrolling Interest Sharing Ratio	-629.91%	105.87%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.43	11.49	6.20	4.24	1.26	1.27	1.16	1.13	0.97	1.17	0.95
Quick Ratio	0.16	11.35	6.07	4.09	1.19	1.20	1.08	1.05	0.82	1.07	0.77
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.95	-16	-53	-57	16	11	-283	15	-432	274	-251
Operating Cash Flow to CapEx	-224,337.50%	-5,957.73%	-15,734.38%	-6,769.49%	3,092.75%	431.55%	1,693.87%	5,327.01%	7,659.06%	59,598.48%	12,407.99%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-562.04	0.00	0.79	12.01	-9.80	0.71	-6.84	2.56	-2.94
Operating Cash Flow to Interest Expense	0.00	0.00	-798.44	0.00	8.41	30.56	3.25	4.93	1.97	2.57	2.40
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-803.51	0.00	8.14	23.48	3.06	4.84	1.94	2.57	2.38
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.01	0.19	1.31	0.99	0.65	0.41	0.50	0.49	0.45
Accounts Receivable Turnover	0.00	0.00	0.00	4.71	6.38	3.93	3.97	2.93	3.21	3.13	3.09
Inventory Turnover	0.00	0.00	0.00	1.66	34.41	22.18	10.31	7.65	7.96	6.10	7.49
Fixed Asset Turnover	0.00	0.00	1.93	19.89	50.52	28.09	20.10	14.39	23.78	31.93	41.66
Accounts Payable Turnover	0.00	0.00	0.03	0.35	18.58	21.05	16.01	17.78	66.24	39.49	40.25
Days Sales Outstanding (DSO)	0.00	0.00	0.00	77.53	57.22	92.82	91.99	124.69	113.67	116.77	117.94
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	220.05	10.61	16.45	35.41	47.71	45.83	59.80	48.76
Days Payable Outstanding (DPO)	0.00	0.00	10,832.62	1,040.14	19.64	17.34	22.80	20.53	5.51	9.24	9.07
Cash Conversion Cycle (CCC)	0.00	0.00	-10,832.62	-742.55	48.18	91.93	104.60	151.87	153.99	167.33	157.63
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-0.95	-3.91	-17	-13	-44	-71	266	264	720	552	923
Invested Capital Turnover	0.00	0.00	-0.16	-1.89	-9.88	-5.18	3.17	1.04	0.94	0.89	0.86
Increase / (Decrease) in Invested Capital	-0.95	-2.96	-13	3.70	-30	-28	338	-2.52	456	-168	370
Enterprise Value (EV)	0.00	480	294	484	436	531	776	709	1,306	1,360	1,618
Market Capitalization	0.00	569	445	601	571	690	693	646	779	1,004	924
Book Value per Share	($95.66)	$4.11	$4.72	$3.20	$2.75	$2.61	$5.38	$5.87	$5.80	$5.99	$7.10
Tangible Book Value per Share	($95.66)	$4.11	$4.64	$3.20	$1.42	$1.73	($4.33)	($1.90)	($15.08)	($11.04)	($25.58)
Total Capital	0.77	92	136	106	103	99	443	453	896	863	1,110
Total Debt	13	6.81	1.48	1.48	12	12	257	250	701	667	881
Total Long-Term Debt	6.81	4.15	1.48	0.00	9.86	7.67	210	202	538	484	788
Net Debt	11	-89	-152	-117	-135	-159	83	64	527	357	694
Capital Expenditures (CapEx)	0.01	0.36	0.48	0.99	5.48	6.44	5.55	1.94	1.62	0.46	1.65
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.36	-4.58	-20	-15	-97	-112	-88	-102	-25	-48	-121
Debt-free Net Working Capital (DFNWC)	0.27	91	133	103	50	58	86	84	149	263	66
Net Working Capital (NWC)	-5.92	88	133	102	48	54	38	36	-14	80	-27
Net Nonoperating Expense (NNE)	0.00	8.42	28	22	25	6.10	28	-59	48	58	50
Net Nonoperating Obligations (NNO)	11	-89	-152	-117	-135	-159	80	61	525	357	694
Total Depreciation and Amortization (D&A)	0.16	0.14	0.62	0.56	111	15	71	72	147	157	173
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-1,183.28%	-53.46%	-34.45%	-37.83%	-28.45%	-36.88%	-5.37%	-8.39%	-19.24%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	7,772.00%	363.38%	17.84%	19.48%	27.72%	30.46%	32.07%	46.41%	10.50%
Net Working Capital to Revenue	0.00%	0.00%	7,772.00%	358.18%	17.26%	18.19%	12.40%	12.99%	-2.96%	14.06%	-4.32%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($22.72)	($1.48)	($3.88)	($2.47)	($1.19)	($0.68)	$0.00	$0.00	$0.00	$1.43	$2.14
Adjusted Weighted Average Basic Shares Outstanding	934.00K	23.51M	29.45M	32.99M	33.31M	34.05M	0.00	0.00	0.00	33.74M	32.27M
Adjusted Diluted Earnings per Share	($22.72)	($1.48)	($94,176,000.00)	($2.47)	($1.19)	($0.68)	$0.00	$0.00	$0.00	$1.29	$1.86
Adjusted Weighted Average Diluted Shares Outstanding	934.00K	23.51M	29.45M	32.99M	33.31M	34.05M	0.00	0.00	0.00	41.79M	40.42M
Adjusted Basic & Diluted Earnings per Share	($22.72)	($1.48)	($94,176,000.00)	($2.47)	($1.19)	($0.68)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	934.00K	13.54M	24.26M	30.27M	32.95M	33.45M	0.00	0.00	0.00	31.96M	31.49M
Normalized Net Operating Profit after Tax (NOPAT)	0.00	-19	-66	-53	-14	-17	55	16	23	106	117
Normalized NOPAT Margin	0.00%	0.00%	-3,849.06%	-185.46%	-5.16%	-5.60%	17.59%	5.61%	5.03%	18.73%	18.56%
Pre Tax Income Margin	0.00%	0.00%	-5,504.15%	-262.91%	-13.95%	-7.66%	8.90%	-1.22%	-6.22%	13.36%	15.61%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-1,000.87	0.00	-1.03	-26.13	1.95	0.84	0.53	1.56	1.99
NOPAT to Interest Expense	0.00	0.00	-700.61	0.00	-0.72	-18.29	1.89	0.59	0.37	0.99	1.40
EBIT Less CapEx to Interest Expense	0.00	0.00	-1,005.95	0.00	-1.30	-33.21	1.75	0.75	0.50	1.56	1.97
NOPAT Less CapEx to Interest Expense	0.00	0.00	-705.69	0.00	-0.99	-25.37	1.70	0.49	0.34	0.99	1.38
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	-0.08%	0.00%	0.00%	66.92%	-56.25%	155.75%	86.75%

This table displays calculated financial ratios and metrics derived from Collegium Pharmaceutical's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	61.10%	373.72%	72.85%	9.71%	7.63%	15.53%	0.11%	7.18%	16.53%	21.51%
EBITDA Growth	89.21%	455.02%	518.80%	47.05%	37.30%	72.15%	32.33%	10.07%	-7.69%	-2.92%
EBIT Growth	44.65%	134.46%	345.90%	220.73%	119.93%	424.69%	100.89%	33.22%	-22.60%	-38.22%
NOPAT Growth	-48.15%	134.46%	345.90%	234.87%	394.04%	412.54%	117.17%	22.82%	-35.31%	-34.41%
Net Income Growth	-94.32%	71.24%	-33.34%	350.57%	4,415.10%	543.67%	259.03%	50.73%	-54.76%	-60.75%
EPS Growth	-95.45%	62.50%	-30.77%	326.67%	5,200.00%	542.86%	239.22%	52.94%	-49.06%	-61.29%
Operating Cash Flow Growth	147.88%	83.23%	209.31%	146.53%	73.06%	10.57%	123.83%	-32.41%	-112.16%	15.42%
Free Cash Flow Firm Growth	-1,823.90%	-1,993.69%	128.11%	144.01%	144.32%	146.87%	30.40%	-23.74%	-263.89%	-263.48%
Invested Capital Growth	208.72%	172.62%	-17.46%	-23.14%	-25.48%	-23.28%	-25.47%	-21.03%	68.66%	67.11%
Revenue Q/Q Growth	2.80%	2.05%	11.69%	-6.37%	0.86%	9.54%	-3.22%	0.24%	9.65%	14.22%
EBITDA Q/Q Growth	17.74%	-6.12%	13.89%	16.81%	9.94%	17.71%	-12.45%	-2.84%	-7.80%	23.80%
EBIT Q/Q Growth	84.22%	-42.56%	109.47%	44.69%	26.32%	37.04%	-19.80%	-4.05%	-26.61%	9.39%
NOPAT Q/Q Growth	-16.01%	26.00%	109.47%	51.07%	23.91%	30.72%	-11.25%	-14.56%	-34.74%	32.53%
Net Income Q/Q Growth	108.80%	-1,675.27%	-142.06%	174.64%	58.64%	54.79%	-13.23%	-29.25%	-52.39%	34.29%
EPS Q/Q Growth	106.67%	-2,200.00%	-142.86%	166.67%	55.88%	75.47%	-23.66%	-26.76%	-48.08%	33.33%
Operating Cash Flow Q/Q Growth	5.73%	55.08%	-58.28%	260.38%	-25.78%	-0.92%	-15.55%	8.82%	-113.35%	1,040.59%
Free Cash Flow Firm Q/Q Growth	-6.95%	14.55%	137.24%	29.31%	7.71%	-9.64%	3.11%	-24.39%	-331.48%	9.86%
Invested Capital Q/Q Growth	-4.20%	-8.23%	-1.88%	-10.90%	-7.11%	-5.52%	-4.50%	-5.60%	98.39%	-6.39%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	46.33%	38.41%	53.47%	54.47%	58.75%	63.19%	63.11%	62.51%	60.76%	54.02%
EBITDA Margin	48.01%	44.16%	45.04%	56.18%	61.24%	65.81%	59.53%	57.70%	48.51%	52.58%
Operating Margin	16.11%	9.07%	17.01%	26.29%	32.93%	41.20%	34.14%	32.68%	21.87%	20.95%
EBIT Margin	16.11%	9.07%	17.01%	26.29%	32.93%	41.20%	34.14%	32.68%	21.87%	20.95%
Profit (Net Income) Margin	0.36%	-5.55%	-12.04%	9.60%	15.09%	21.33%	19.12%	13.50%	5.86%	6.89%
Tax Burden Percent	31.91%	92.40%	99.25%	73.09%	71.69%	68.38%	75.67%	67.38%	59.92%	72.59%
Interest Burden Percent	7.00%	-66.27%	-71.29%	49.95%	63.94%	75.72%	74.02%	61.29%	44.72%	45.31%
Effective Tax Rate	68.09%	0.00%	0.00%	26.91%	28.31%	31.62%	24.33%	32.62%	40.08%	27.41%
Return on Invested Capital (ROIC)	3.58%	5.99%	8.01%	14.25%	18.86%	25.11%	23.77%	22.56%	10.00%	13.02%
ROIC Less NNEP Spread (ROIC-NNEP)	1.46%	0.72%	2.16%	11.77%	16.51%	22.79%	21.43%	19.06%	8.01%	10.14%
Return on Net Nonoperating Assets (RNNOA)	1.79%	1.06%	6.81%	30.99%	43.57%	51.46%	44.27%	32.35%	22.42%	25.11%
Return on Equity (ROE)	5.38%	7.05%	14.82%	45.24%	62.43%	76.57%	68.04%	54.91%	32.43%	38.13%
Cash Return on Invested Capital (CROIC)	-103.83%	-87.91%	25.23%	35.12%	36.46%	43.04%	51.55%	49.10%	-34.05%	-34.07%
Operating Return on Assets (OROA)	6.00%	4.51%	7.26%	11.48%	15.13%	20.15%	16.62%	16.62%	9.32%	9.42%
Return on Assets (ROA)	0.13%	-2.76%	-5.14%	4.19%	6.94%	10.43%	9.31%	6.86%	2.50%	3.10%
Return on Common Equity (ROCE)	5.38%	7.05%	14.82%	45.24%	62.43%	76.57%	68.04%	54.91%	32.43%	38.13%
Return on Equity Simple (ROE_SIMPLE)	-21.72%	0.00%	-16.33%	-5.56%	5.04%	0.00%	41.99%	46.12%	37.82%	0.00%
Net Operating Profit after Tax (NOPAT)	6.53	8.23	17	26	32	42	37	32	21	28
NOPAT Margin	5.14%	6.35%	11.91%	19.21%	23.60%	28.17%	25.83%	22.02%	13.10%	15.21%
Net Nonoperating Expense Percent (NNEP)	2.12%	5.27%	5.85%	2.49%	2.35%	2.32%	2.34%	3.50%	2.00%	2.88%
Return On Investment Capital (ROIC_SIMPLE)	-	0.92%	-	-	-	4.89%	-	-	-	2.49%
Cost of Revenue to Revenue	53.67%	61.59%	46.53%	45.53%	41.25%	36.81%	36.89%	37.49%	39.24%	45.98%
SG&A Expenses to Revenue	30.21%	29.34%	36.46%	28.18%	25.82%	22.00%	28.97%	29.83%	38.89%	34.68%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	30.21%	29.34%	36.46%	28.18%	25.82%	22.00%	28.97%	29.83%	38.89%	33.07%
Earnings before Interest and Taxes (EBIT)	20	12	25	36	45	62	49	47	35	38
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	61	57	65	76	84	99	86	84	77	96
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.77	4.00	4.55	3.70	4.34	5.14	5.70	4.86	5.31	4.04
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.51	1.68	1.56	1.38	1.42	1.77	2.23	1.83	2.08	1.46
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	86.10	20.84	13.57	10.55	14.05	13.35
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	1.16%	4.80%	7.37%	9.48%	7.12%	7.49%
Enterprise Value to Invested Capital (EV/IC)	1.45	1.82	1.91	1.86	2.02	2.46	2.99	2.69	2.03	1.75
Enterprise Value to Revenue (EV/Rev)	3.14	2.82	2.56	2.18	2.16	2.40	2.77	2.31	3.33	2.56
Enterprise Value to EBITDA (EV/EBITDA)	10.60	7.23	5.72	4.52	4.19	4.20	4.56	3.79	5.77	4.72
Enterprise Value to EBIT (EV/EBIT)	0.00	39.20	19.81	12.68	10.11	8.15	8.19	6.55	10.32	9.52
Enterprise Value to NOPAT (EV/NOPAT)	0.00	56.00	28.30	18.11	23.80	12.81	11.41	9.26	14.91	13.56
Enterprise Value to Operating Cash Flow (EV/OCF)	12.07	10.51	7.60	4.96	4.42	4.95	5.08	4.82	10.31	7.89
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	6.83	4.61	4.74	4.97	4.95	4.83	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.67	3.60	4.44	3.76	3.98	3.41	2.80	2.55	3.83	3.85
Long-Term Debt to Equity	2.95	2.76	3.42	2.85	2.95	2.48	1.98	1.71	3.43	3.44
Financial Leverage	1.23	1.47	3.15	2.63	2.64	2.26	2.07	1.70	2.80	2.48
Leverage Ratio	4.17	4.69	6.55	6.17	6.32	5.94	5.79	5.43	6.81	6.62
Compound Leverage Factor	0.29	-3.11	-4.67	3.08	4.04	4.50	4.29	3.33	3.04	3.00
Debt to Total Capital	78.58%	78.25%	81.62%	78.99%	79.90%	77.34%	73.72%	71.85%	79.28%	79.39%
Short-Term Debt to Total Capital	15.39%	18.14%	18.74%	19.19%	20.60%	21.25%	21.69%	23.83%	8.27%	8.42%
Long-Term Debt to Total Capital	63.20%	60.11%	62.88%	59.80%	59.30%	56.09%	52.03%	48.02%	71.00%	70.96%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	21.42%	21.75%	18.38%	21.01%	20.10%	22.66%	26.28%	28.15%	20.72%	20.61%
Debt to EBITDA	6.75	3.88	3.39	2.91	2.52	2.06	1.81	1.57	2.59	2.57
Net Debt to EBITDA	5.50	2.92	2.25	1.65	1.44	1.10	0.89	0.80	2.17	2.02
Long-Term Debt to EBITDA	5.43	2.98	2.61	2.20	1.87	1.50	1.28	1.05	2.32	2.30
Debt to NOPAT	-82.30	30.05	16.78	11.66	14.31	6.28	4.52	3.84	6.69	7.39
Net Debt to NOPAT	-67.04	22.61	11.12	6.63	8.18	3.36	2.21	1.95	5.61	5.82
Long-Term Debt to NOPAT	-66.19	23.09	12.93	8.83	10.62	4.56	3.19	2.56	5.99	6.61
Altman Z-Score	0.36	0.56	0.71	0.75	0.82	1.11	1.35	1.26	0.81	0.68
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.98	0.97	1.21	1.24	1.16	1.17	1.21	1.11	0.97	0.95
Quick Ratio	0.80	0.82	1.09	1.13	1.05	1.07	1.10	0.99	0.76	0.77
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-524	-447	167	215	232	210	217	164	-380	-343
Operating Cash Flow to CapEx	37,848.67%	7,055.85%	15,722.16%	178,075.00%	113,873.85%	44,718.29%	10,904.40%	24,962.22%	-3,688.11%	14,849.82%
Free Cash Flow to Firm to Interest Expense	-27.49	-21.74	3.71	9.85	11.17	10.88	12.53	7.22	-16.87	-15.13
Operating Cash Flow to Interest Expense	2.25	3.22	0.62	4.56	3.56	3.80	3.57	2.96	-0.40	3.74
Operating Cash Flow Less CapEx to Interest Expense	2.24	3.18	0.61	4.56	3.56	3.80	3.54	2.95	-0.41	3.71
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.37	0.50	0.43	0.44	0.46	0.49	0.49	0.51	0.43	0.45
Accounts Receivable Turnover	2.10	3.21	3.04	2.94	2.90	3.13	3.20	3.28	2.92	3.09
Inventory Turnover	4.96	7.96	5.07	5.34	5.37	6.10	7.07	8.14	6.25	7.49
Fixed Asset Turnover	18.37	23.78	26.86	28.26	30.04	31.93	33.02	34.93	38.34	41.66
Accounts Payable Turnover	26.46	66.24	83.75	61.26	47.00	39.49	50.31	90.83	66.39	40.25
Days Sales Outstanding (DSO)	173.78	113.67	120.10	124.05	125.95	116.77	113.90	111.19	124.96	117.94
Days Inventory Outstanding (DIO)	73.62	45.83	71.99	68.36	67.95	59.80	51.66	44.81	58.38	48.76
Days Payable Outstanding (DPO)	13.79	5.51	4.36	5.96	7.77	9.24	7.25	4.02	5.50	9.07
Cash Conversion Cycle (CCC)	233.61	153.99	187.74	186.46	186.13	167.33	158.30	151.99	177.84	157.63
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	784	720	706	629	584	552	526	497	985	923
Invested Capital Turnover	0.70	0.94	0.67	0.74	0.80	0.89	0.92	1.02	0.76	0.86
Increase / (Decrease) in Invested Capital	530	456	-149	-189	-200	-168	-180	-132	401	370
Enterprise Value (EV)	1,136	1,306	1,346	1,173	1,183	1,360	1,571	1,335	1,996	1,618
Market Capitalization	547	779	817	743	776	1,004	1,266	1,053	1,245	924
Book Value per Share	$5.78	$5.80	$5.28	$5.80	$5.15	$5.99	$6.87	$6.62	$7.27	$7.10
Tangible Book Value per Share	($15.90)	($15.08)	($14.21)	($12.30)	($11.84)	($11.04)	($9.25)	($8.25)	($26.65)	($25.58)
Total Capital	921	896	978	956	890	863	845	769	1,130	1,110
Total Debt	724	701	798	755	711	667	623	553	896	881
Total Long-Term Debt	582	538	615	571	528	484	440	369	803	788
Net Debt	589	527	529	429	406	357	305	281	751	694
Capital Expenditures (CapEx)	0.11	0.94	0.18	0.06	0.07	0.16	0.57	0.27	0.24	0.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.74	-25	-0.55	-40	-49	-48	-42	-40	-67	-121
Debt-free Net Working Capital (DFNWC)	132	149	269	286	256	263	276	232	78	66
Net Working Capital (NWC)	-9.28	-14	86	102	72	80	93	48	-16	-27
Net Nonoperating Expense (NNE)	6.07	15	35	13	12	10	9.73	12	12	15
Net Nonoperating Obligations (NNO)	587	525	526	428	405	357	304	280	751	694
Total Depreciation and Amortization (D&A)	41	45	41	41	39	37	37	36	42	58
Debt-free, Cash-free Net Working Capital to Revenue	-0.48%	-5.37%	-0.10%	-7.43%	-8.92%	-8.39%	-7.39%	-6.90%	-11.19%	-19.24%
Debt-free Net Working Capital to Revenue	36.60%	32.07%	51.23%	53.18%	46.80%	46.41%	48.71%	40.20%	13.00%	10.50%
Net Working Capital to Revenue	-2.57%	-2.96%	16.31%	19.04%	13.26%	14.06%	16.37%	8.41%	-2.61%	-4.32%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.01	($0.21)	($0.51)	$0.38	$0.61	$0.95	$0.86	$0.60	$0.29	$0.39
Adjusted Weighted Average Basic Shares Outstanding	34.06M	33.83M	34.32M	34.62M	33.74M	33.74M	32.33M	32.43M	32.26M	32.27M
Adjusted Diluted Earnings per Share	$0.01	($0.21)	($0.51)	$0.34	$0.53	$0.93	$0.71	$0.52	$0.27	$0.36
Adjusted Weighted Average Diluted Shares Outstanding	34.57M	33.83M	34.32M	42.85M	42.06M	41.79M	41.44M	40.38M	40.16M	40.42M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	33.57M	34.07M	34.59M	34.73M	32.61M	31.96M	32.72M	32.21M	32.25M	31.49M
Normalized Net Operating Profit after Tax (NOPAT)	14	8.23	17	26	32	42	37	32	21	28
Normalized NOPAT Margin	11.28%	6.35%	11.91%	19.21%	23.60%	28.17%	25.83%	22.02%	13.10%	15.21%
Pre Tax Income Margin	1.13%	-6.01%	-12.13%	13.13%	21.05%	31.19%	25.27%	20.03%	9.78%	9.49%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.07	0.57	0.55	1.63	2.17	3.20	2.85	2.08	1.55	1.68
NOPAT to Interest Expense	0.34	0.40	0.38	1.19	1.55	2.19	2.16	1.40	0.93	1.22
EBIT Less CapEx to Interest Expense	1.07	0.53	0.54	1.63	2.16	3.19	2.82	2.07	1.53	1.66
NOPAT Less CapEx to Interest Expense	0.34	0.35	0.38	1.19	1.55	2.18	2.13	1.39	0.92	1.20
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-90.48%	-56.25%	-47.90%	-126.00%	639.32%	155.75%	80.39%	110.12%	67.72%	86.75%

Frequently Asked Questions About Collegium Pharmaceutical's Financials

When does Collegium Pharmaceutical's fiscal year end?

According to the most recent income statement we have on file, Collegium Pharmaceutical's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Collegium Pharmaceutical's net income changed over the last 10 years?

Collegium Pharmaceutical's net income appears to be on a downward trend, with a most recent value of $69.19 million in 2024, rising from $0.00 in 2014. The previous period was $48.16 million in 2023.

What is Collegium Pharmaceutical's operating income?

Collegium Pharmaceutical's total operating income in 2024 was $169.90 million, based on the following breakdown:

Total Gross Profit: $377.34 million
Total Operating Expenses: $207.45 million

How has Collegium Pharmaceutical revenue changed over the last 10 years?

Over the last 10 years, Collegium Pharmaceutical's total revenue changed from $0.00 in 2014 to $631.45 million in 2024, a change of 63,144,900,000.0%.

How much debt does Collegium Pharmaceutical have?

Collegium Pharmaceutical's total liabilities were at $1.43 billion at the end of 2024, a 51.4% increase from 2023, and a 8,178.5% increase since 2014.

How much cash does Collegium Pharmaceutical have?

In the past 10 years, Collegium Pharmaceutical's cash and equivalents has ranged from $1.63 million in 2014 to $238.95 million in 2023, and is currently $70.57 million as of their latest financial filing in 2024.

How has Collegium Pharmaceutical's book value per share changed over the last 10 years?

Over the last 10 years, Collegium Pharmaceutical's book value per share changed from -95.66 in 2014 to 7.10 in 2024, a change of -107.4%.

Remove Ads

Related Companies

This page (NASDAQ:COLL) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Collegium Pharmaceutical (COLL) Financials

Frequently Asked Questions About Collegium Pharmaceutical's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Collegium Pharmaceutical (COLL) Financials

Annual Income Statements for Collegium Pharmaceutical

Quarterly Income Statements for Collegium Pharmaceutical

Annual Cash Flow Statements for Collegium Pharmaceutical

Quarterly Cash Flow Statements for Collegium Pharmaceutical

Annual Balance Sheets for Collegium Pharmaceutical

Quarterly Balance Sheets for Collegium Pharmaceutical

Annual Metrics and Ratios for Collegium Pharmaceutical

Quarterly Metrics and Ratios for Collegium Pharmaceutical

Frequently Asked Questions About Collegium Pharmaceutical's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools